Log In
Print
BCIQ
Print
Print this Print this
 

lirilumab (BMS-986015, IPH2102)

Also known as: IPH 2102

  Manage Alerts
Collapse Summary General Information
Company Innate Pharma S.A.
DescriptionHuman anti-killer cell immunoglobulin-like receptors (KIR) mAb
Molecular Target Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 (KIR2DL1) ; Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 2 (KIR2DL2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$465.0M

$35.0M

$430.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today